Abstract
The dopaminergic neuronal loss in the substantia nigra pars compacta (SNc) has been related to a reduction of neuromelanin (NM) and accumulation of iron in the nigrosome-1 (N1) in Parkinson’s disease (PD). This suggests that N1 degeneration could be a promising early biomarker of PD. To date, only qualitative visual scales have been used to assess its degeneration in iron-sensitive images. Here we present the first fully-automatic method for the quantification of NM and iron content in the N1. Our method uses a multi-image atlas populated with healthy N1 structures that implements a customised label fusion strategy to segment the N1. NM-MRI and susceptibility-weighted images (SWI) of 71 PD patients and 30 healthy controls (HCs) were used in the study. Our quantification showed that N1’s NM content was reduced and the iron content increased in PD patients compared with HCs. ROC analyses showed the high diagnostic potential of N1, and revealed that the N1 alone was more sensitive than the entire SNc to detect abnormal iron accumulations in PD patients. Multi-parametric binary logistic regression showed that computer-assisted diagnosis methods could benefit from the segmentation of the N1 to boost their performance. A significant correlation was also found between most N1 image parameters and both disease duration and the motor status scored with the Unified Parkinson’s disease rating scale part III (UDPRS-III), suggesting a NM reduction along with an iron accumulation in N1 as the disease progresses. In addition, voxel-wise analyses revealed that this association was stronger for the N1 than for the entire SNc, highlighting the benefits of an accurate segmentation of the N1 to monitor disease course.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by RTI2018-094494-B-C22 and PDI2021-122409OB-C22 (to C.O.S) and SAF2016-81016-R (to M.A.P) grants from the Spanish Ministry of Science and Innovation and Universities (MCIU/AEI/FEDER, UE).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Navarra Research Ethics Committee, and written informed consent was obtained from all subjects.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Funding This work was supported by FEDER and MCIN/AEI /10.13039/501100011033/ [grant numbers RTI2018-094494-B-C22 (C.O.S) and SAF2016-81016-R (M.A.P)]. The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data and the final responsibility to submit for publication.
Data Availability
The data and code reported in this study will be made publicly available upon acceptance of the manuscript. In the meantime, they will be available for reviewers upon request to the corresponding author C. Ortiz de Solorzano.
Abbreviations
- AUC
- area under the curve
- CR
- contrast ratio
- DSC
- dice similarity coefficient
- GWV
- global weighted voting
- HC
- healthy control
- LWV
- local weighted voting
- MV
- majority voting
- N1
- nigrosome-1
- NM
- neuromelanin
- NMI
- normalized mutual information
- nVol
- normalized volume
- PD
- Parkinson’s disease
- SN
- substantia nigra
- SNc
- substantia nigra pars compacta
- SNr
- substantia nigra pars reticulata
- SWI
- susceptibility-weighted imaging
- UPDRS-III
- unified Parkinson’s disease rating scale part-III.
